Skuldtech is specialized in the discovery of genomic biomarkers and the development of diagnostics focused on personalized medicine applications.
Skuldtech is positioned in the field of “personalized medicine,” which takes people’s biological and physiological differences into account in order to administer the most effective treatments, adapted to match the profile of each patient. The company’s products include diagnostics such as “patient stratification” tests and “companion” diagnostics that enable stratifying and segmenting patients according to “typical profiles.”
Skuldtech is involved in personalized medicine due to its technique and know-how enabling to identify genomic biomarkers associated with gene expression – phenotypes – changes. The company is working towards developing daily practice tools on the basis of new identified genomic biomarkers.
A patient's response to a specific medication may not simply be determined by a single gene, but by several genes and their interacting products. Skuldtech's genomic biomarkers can meet this challenge in personalized medicine.
The biomarkers developed in this way by Skuldtech can be used for:
- Diagnosing diseases or predicting risks of disease,
- Determining whether a treatment is efficient or not,
- Monitoring healthy people to detect early signs of disease,
- Producing safer drugs by predicting the potential for adverse effects earlier,
- Targeting specific groups of people for whom a particular drug may be useful, while not using it for those for whom it may prove harmful,
- Providing researchers with the opportunity of having a global view of the events and changes that are always occurring within a cell.
Greater progress may be made in personalized medicine through using molecular genomic-based diagnostics.
Skuldtech is involved in the development of companion diagnostics which can be defined as a diagnostic specifically associated with a therapy.
Therefore, Skuldtech is focusing its biomarker strategy for the companion diagnosis purpose on gene expression changes under drugs regimes. Gene expression signatures can predict patients' response to treatment. These gene expression changes can also be used as predictors and modulators of cellular sensitivity to cancer chemotherapeutics, for instance.
- Selection of optimal therapy,
- Reduction of Adverse Drug Reactions,
- Treatment monitoring,
- Reduction of clinical trial costs, duration and failure rates,
- Drug rescue: off-market drugs and failing trials.
Companion Diagnostics could revolutionize medical practices by enabling to prescribe safer and more effective drugs for patients with clearly identified biomarkers. Our aim is to deliver “the right dose of the right drug to the right patient at the right time”
If you need more information, please contact our business development department
(T: +33(0)467 419 748, Email: info@skuldtech.com).
Skuldtech is specialized in the discovery of
Biomarkers and the development of Diagnostics
focused on personalized medicine applications.
This expertise enables the company to provide
genomic, pharmacogenomic and transcriptomic services,
as well as innovative diagnostics
associated with new
therapeutics especially in
cancer, rare diseases and
infectious diseases.